🇬🇧Start here for UK care. Licensed weight-management medicines are available, but NHS access depends on your nation, local pathway and clinical criteria. Private treatment requires its own assessment. Compare ongoing care and GBP costs after establishing which route is appropriate.
Read the country guide →🇮🇪Ireland illustrates the gap between a medicine being prescribed and a reimbursement decision being implemented. The HSE's patient guidance and the latest NCPE assessment answer different parts of that question.
Read the country guide →🇩🇪In Germany, approval for weight management and statutory health-insurance reimbursement are distinct. The legal exclusion affecting weight-loss medicines can matter more to the patient's bill than the European licence.
Read the country guide →🇫🇷France introduced restricted reimbursement for Wegovy and Mounjaro in June 2026. The permitted prescribing indication is broader than the group eligible for reimbursement, and the paperwork is part of the pathway.
Read the country guide →🇪🇸Spain provides separate public sources for a medicine's technical information and its national funding status. Reading both avoids confusing an authorised weight-management treatment with an SNS-funded prescription.
Read the country guide →🇺🇸US access depends on the FDA-approved product and indication, the prescriber's assessment and the payment route. The 2026 Medicare GLP-1 Bridge makes older blanket statements about Medicare weight-management access incomplete.
Read the country guide →🇨🇦Health Canada authorisation establishes a medicine's regulatory status. Provincial or other public drug-plan decisions and private benefits determine payment. A national reimbursement recommendation does not by itself provide coverage across Canada.
Read the country guide →🇲🇽Mexico's COFEPRIS records are the starting point for checking a product's registration. Registration, a clinic's ability to supply it and payment through a particular health institution or insurer should be verified separately.
Read the country guide →🇧🇷Brazil's GLP-1 landscape is changing through new authorisations and work on possible SUS provision. Regulatory progress should not be confused with a fully implemented public treatment pathway or a guaranteed pharmacy price.
Read the country guide →🇨🇱Chile's ISP provides product information for authorised medicines and a separate route for checking pharmacies permitted to sell online. Both are useful when comparing treatment offers, but neither establishes insurance payment.
Read the country guide →🇮🇳India's central approval records and 2026 prescribing communications are more useful than launch advertising for establishing access. The exact product, approved indication and permitted prescriber all matter when comparing an offer.
Read the country guide →🇯🇵Japan's obesity-treatment pathway includes optimal-use guidance and requirements for the medical institution, as well as patient eligibility. A self-pay clinic offer should not be treated as evidence of access through public health insurance.
Read the country guide →🇦🇪The Emirates Drug Establishment provides a national registered-product directory, while the patient's clinical service and insurer determine practical access and payment. A registration announcement should not be read as guaranteed pharmacy stock.
Read the country guide →🇿🇦South Africa's current product information is essential: older online statements predate later weight-management approvals. SAHPRA's approved documents and its more recent enforcement notices should be read for their different purposes.
Read the country guide →🇰🇪Kenya's Pharmacy and Poisons Board publishes medicine information and tools for verifying licensed pharmacy premises. Those checks provide a firmer starting point than an online stock claim, while funding and availability still need local confirmation.
Read the country guide →🇪🇬Egypt's Drug Authority publishes a Wegovy assessment report and separate national formulary information on semaglutide. Reading the product and indication together is essential; an ingredient name alone does not describe the approved treatment.
Read the country guide →🇦🇺Australia separates TGA medicine registration from PBS subsidy. New formulations and funding recommendations can make headlines before a patient can obtain the treatment at a subsidised pharmacy price.
Read the country guide →🇳🇿New Zealand separates Medsafe approval from Pharmac funding. Pharmac's November 2026 update says Wegovy and Mounjaro remain unfunded. These decisions do not determine UK access.
Read the country guide →